

# From Guidance to Practice: Key Updates in the 2025 BHIVA HIV Pregnancy Guidelines.

Jen Kendrick

Clinical Nurse Specialist

Manchester University NHS Foundation Trust

## Conflict of Interest

In relation to this presentation, I declare that I have no conflict of interest.

Speakers are required by the Federation of the Royal Colleges of Physicians to disclose conflicts of interest at the beginning of their presentation, with sufficient time for the information to be read by the audience. They should disclose financial relationships with manufacturers of any commercial product and/or providers of commercial services used on or produced for patients relating to the 36 months prior to the event. These include speaker fees, research grants, fees for other educational activities such as training of health professionals and consultation fees. Where a speaker owns shares or stocks directly in a company producing products or services for healthcare this should also be declared. Finally, other conflicts of interest including expert functions in health care or healthcare guidance processes should be declared (eg if the professional is a member of a health board). The Federation considers it good practice to also make speakers' disclosures available in digital format(s) relating to the educational event.

# Session Overview

## Aims of this Session

By the end of this session participants will be able to:

- Summarise key updates in the 2025 BHIVA Pregnancy Guidelines
- Identify major changes affecting clinical practice
- Describe updates to infant postnatal prophylaxis (PNP)
- Discuss current breastfeeding guidance
- Consider implications for HIV specialist nursing practice
- Apply the updated guidance through a clinical case study

# Why Were the Guidelines Updated?

## Background

The 2025 BHIVA Pregnancy Guidelines have been revised to:

- Reflect evolving evidence for pregnant people living with HIV
- Incorporate new ART safety and efficacy data
- Simplify neonatal prophylaxis pathways
- Support informed infant-feeding choices
- Strengthen person-centred and shared decision-making approaches
- Improve consistency of care across maternity and HIV services

**Overall Goal-** Maintain elimination of vertical HIV transmission while supporting personalised care.

# Key Changes at a Glance

| • Area                | • Previous Approach                         | • 2025 Update                                                                        | • Impact on Practice                                      |
|-----------------------|---------------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------|
| • Infant Feeding      | • Formula feeding generally recommended     | • Supports informed breastfeeding choice for people with sustained viral suppression | • Greater emphasis on shared decision-making              |
| • Infant PNP          | • Multiple risk categories and regimens     | • Simplified into <b>Low-Risk</b> and <b>High-Risk</b> pathways                      | • Easier prescribing and counselling                      |
| • ART in Pregnancy    | • Based on earlier evidence                 | • Updated to reflect current ART guidance and safety data                            | • Improved consistency of care                            |
| • HIV Prevention      | • Limited focus during pregnancy/postpartum | • New guidance on HIV acquisition prevention and serodifferent couples               | • Enhanced prevention strategies                          |
| • Postpartum Care     | • Less detailed follow-up recommendations   | • Expanded maternal follow-up and retention in care guidance                         | • Improved long-term outcomes                             |
| • Obstetric Care      | • Standard pregnancy surveillance           | • Additional focus on fetal growth restriction (FGR) and preterm birth assessment    | • Earlier identification of complications                 |
| • Peer Support        | • Variable access and referral practices    | • Greater emphasis on offering peer support throughout pregnancy and postpartum care | • Improves engagement, empowerment and patient experience |
| • Person-Centred Care | • Included but less explicit                | • Strong emphasis on informed choice and shared decision-making                      | • More individualised care                                |

# Key Area 1 – Infant Feeding Guidance

## What's New?

### Dedicated chapter

Infant-feeding guidance brought into focus

### Informed choice

Supports parental decision-making

### Breastfeeding support

Where viral suppression is maintained

| • Clinical Update                                          | • What This Means for the Woman/Parent                                                                |
|------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| • Informed feeding choice is supported                     | • Feels empowered to make feeding decisions that align with personal, cultural and family preferences |
| • Breastfeeding can be supported in specific circumstances | • May experience reduced stigma and increased autonomy                                                |
| • Enhanced monitoring pathway                              | • Reassurance through ongoing support and safety monitoring                                           |
| • Shared decision-making approach                          | • Encourages partnership rather than directive care                                                   |

# Infant Feeding Guidance

| Topic                                    | Formula feeding                | Breast/chest feeding                                         |
|------------------------------------------|--------------------------------|--------------------------------------------------------------|
| <b>HIV transmission risk</b>             | Nil                            | Very low risk when maternal viral load remains undetectable  |
| <b>BHIVA position</b>                    | Supported                      | Supported through informed choice and shared decision-making |
| <b>Maternal ART</b>                      | Required                       | Required                                                     |
| <b>Maternal viral load monitoring</b>    | Routine                        | Enhanced monitoring required                                 |
| <b>Infant HIV testing</b>                | Standard testing schedule      | Enhanced testing during feeding and after cessation          |
| <b>Feeding support</b>                   | Routine infant feeding support | Multidisciplinary support recommended                        |
| <b>If maternal VL becomes detectable</b> | N/A                            | Immediate clinical review and feeding discussion required    |
| <b>Documentation</b>                     | Routine                        | Document informed discussion and feeding plan                |

## Infant HIV Testing:

|                                                                                                                                                                      |                                                                                                                                                                                                   |                                                                                                                                              |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| <ul style="list-style-type: none"> <li>• <b>Time Point</b></li> <li>• Birth (within first 48 hours)</li> <li>• 2 weeks of age</li> <li>• 4–6 weeks of age</li> </ul> | <ul style="list-style-type: none"> <li>• <b>Formula-Fed Infant</b></li> <li>• HIV PCR</li> <li>• High-risk infants only</li> <li>• HIV PCR (typically 2 weeks after completion of PNP)</li> </ul> | <ul style="list-style-type: none"> <li>• <b>Breast/Chest-Fed Infant</b></li> <li>• HIV PCR</li> <li>• HIV PCR</li> <li>• HIV PCR</li> </ul>  |
| <ul style="list-style-type: none"> <li>• During breastfeeding</li> </ul>                                                                                             | <ul style="list-style-type: none"> <li>• Not applicable</li> </ul>                                                                                                                                | <ul style="list-style-type: none"> <li>• Monthly HIV PCR during breastfeeding</li> </ul>                                                     |
| <ul style="list-style-type: none"> <li>• 10–12 weeks of age</li> </ul>                                                                                               | <ul style="list-style-type: none"> <li>• HIV PCR (approximately 8 weeks after stopping PNP)</li> </ul>                                                                                            | <ul style="list-style-type: none"> <li>• Not routinely required if breastfeeding continues and monthly testing is being performed</li> </ul> |
| <ul style="list-style-type: none"> <li>• After breastfeeding stops</li> <li>• 8 weeks after breastfeeding stops</li> </ul>                                           | <ul style="list-style-type: none"> <li>• Not applicable</li> <li>• Not applicable</li> </ul>                                                                                                      | <ul style="list-style-type: none"> <li>• HIV PCR at 4 weeks after cessation</li> <li>• HIV PCR at 8 weeks after cessation</li> </ul>         |
| <ul style="list-style-type: none"> <li>• 18–24 months</li> </ul>                                                                                                     | <ul style="list-style-type: none"> <li>• HIV antibody test for seroreversion</li> </ul>                                                                                                           | <ul style="list-style-type: none"> <li>• HIV antibody test for seroreversion</li> </ul>                                                      |



# Key Area 2 – Infant Postnatal Prophylaxis (PNP)

## What's New?

### Simplified categories

Clearer low/high-risk pathways

### Shorter prophylaxis

Reduced medication burden


### Enhanced PNP

When clinically indicated

|                                                          |                                               |
|----------------------------------------------------------|-----------------------------------------------|
|                                                          |                                               |
| Simplified risk categories                               | Easier understanding of infant treatment plan |
| Shorter prophylaxis for low-risk infants                 | Reduced medication burden for baby            |
| Clearer rationale for enhanced prophylaxis when required | Improved understanding of risk and benefit    |
| Consistent national approach                             | Greater confidence in care recommendations    |

## Nursing Consideration

*“Can the family explain why their baby is receiving PNP and for how long?”*



Source: BHIVA pregnancy guideline, Figure 11.1 (infant PNP algorithm).

# Key Area 3 – Updated ART Recommendations

## What's New?

### Updated evidence

Greater ART safety confidence

### Early optimisation

Reduces vertical transmission risk

### Viral suppression

Continued adherence focus

| Clinical Update                 | What This Means for the Woman/Parent                   |
|---------------------------------|--------------------------------------------------------|
| Updated evidence on ART safety  | Increased confidence in treatment during pregnancy     |
| Early ART optimisation          | Reduced risk of vertical transmission                  |
| Continued emphasis on adherence | Opportunity for tailored support when challenges arise |
| Modern ART regimens             | Improved tolerability and treatment experience         |

## Nursing Consideration

*“What barriers might affect adherence during pregnancy and postpartum?”*

# Key Area 4 – HIV Prevention During Pregnancy & Postpartum

## What's New?

### Prevention focus

Ongoing risk recognised

### Serodifferent couples

Inclusive relationship discussions

### PrEP counselling

Shared responsibility for prevention

| Clinical Update                                                 | What This Means for the Woman/Parent                                 |
|-----------------------------------------------------------------|----------------------------------------------------------------------|
| Recognition of HIV acquisition risk in pregnancy and postpartum | Increased awareness of ongoing prevention needs                      |
| Focus on serodifferent couples                                  | More inclusive conversations about relationships and family planning |
| Prevention discussions incorporated into routine care           | Opportunity to address concerns openly                               |
| Partner engagement encouraged                                   | Supports shared responsibility for prevention                        |

## Nursing Consideration

*“Have prevention needs been discussed beyond the immediate pregnancy?”*

# Key Area 5 – Expanded Postpartum Care

## What's New?

### Postpartum engagement

Support after maternity discharge

### Mental wellbeing

Earlier identification of concerns

### Long-term planning

Health of parent and family

| • Clinical Update                         | • What This Means for the Woman/Parent             |
|-------------------------------------------|----------------------------------------------------|
| • Greater focus on postpartum engagement  | • Continued support after maternity discharge      |
| • Increased attention to mental wellbeing | • Earlier identification of emotional difficulties |
| • Retention in HIV care prioritised       | • Reduced risk of loss to follow-up                |
| • Integrated long-term care planning      | • Supports ongoing health of parent and family     |

### Nursing Consideration

*“What support systems will be in place once maternity care ends?”*

# Peer Support & Person-Centred Care

Why Is This a Key Update?

The 2025 guideline places greater emphasis on:

- Peer support
- Shared decision-making
- Empowerment
- Trauma-informed care
- Reducing stigma

# Peer Support & Person-Centred Care Continued

## What's New?

### Peer support

Reduced isolation

### Community networks

Confidence and engagement

### Person-centred care

Therapeutic relationships

| • Clinical Recommendation                                | • Potential Benefit for the Woman/Parent       |
|----------------------------------------------------------|------------------------------------------------|
| • Offer peer support throughout pregnancy and postpartum | • Reduced isolation                            |
| • Signpost to community support networks                 | • Increased confidence and engagement          |
| • Support informed choices                               | • Improved autonomy                            |
| • Person-centred communication                           | • Enhanced trust and therapeutic relationships |

### Nursing Consideration

HIV Specialist Nurses are often the key link between women/parent and peer-support services.



# Case Study

R.N 28-year-old Zimbabwe

- New HIV diagnosis at antenatal booking
- CD4 11, VL 307,000 copies/ml Hb 78
- Immediate ART- TDF/FTC DTG Prophylaxis- Co-Trimoxazole
- Pregnancy- 5mg Folic Acid & Iron Tablets.
- Partner not supportive. Immigration- Visa expired. Peer Navigator Referral.
- Developed oral & genital ulceration- HSV-Aciclovir 5days- Valaciclovir OD
- 22 weeks' gestation- – HIV VL 50 copies/ml CD4 103
- Wishes- NVD and to breast feed.
- Viral Suppression throughout pregnancy- What do you care plan?



# Case Continued

Seen in ANC 39+4- Booked for induction 5 days later.

- VL 68- Obs Cons contacted ANC MDT and GUM on-call.
- Care Plan changed- C-Section and Triple PNP for baby & Formula
- VL Repeated - <50 copies. MDT happy to class as blip.
- Stepped down to Low Risk- NVD, Single PNP and Breast feeding
- Outcome- Emergency C section (failure to progress in labor)
- Paired bloods <50 copies/ml.
- Infant given formula as Mum in theatre.

# Key Take-Home Message

---

Listen to parents' wishes and choices for their pregnancy and delivery.

- Assess parental risk
- Select the appropriate infant prophylaxis pathway
- Support informed feeding choices
- Monitor maternal viral load and infant testing as per appropriate pathway
- Work collaboratively across HIV, maternity and paediatric services

**With the overall goal of:**

*Supporting women and birthing parents living with HIV to achieve healthy pregnancies, make informed choices, and experience positive outcomes for themselves, their babies and their families through person-centred, evidence-based care.*

# References

<https://bhiva.org/clinical-guideline/pregnancy-guidelines/>